Allgenesis to present AG-73305 at Bio Partnering APAC Summit 2021 in Shanghai

Allgenesis Biotherapeutics and AffaMed Therapeutics Announce License Agreement for AG-73305 in Greater China Region
Allgenesis Biotherapeutics Inc. – U.S. Patent Granted for Fusion Protein of VEGF Trap and Disintegrin
Show all

Taipei, Taiwan/ October 26th, 2021

Allgenesis Biotherapeutics Inc., a Taiwan based specialty pharmaceutical company focused on developing novel ophthalmic drugs, will present pre-clinical data for the company’s lead asset AG-73305 at the Bio Partnering APAC Summit 2021 in Shanghai.

The presentation details are as follows:

October 27th, 2021
Project Showcase [Project 10]
Allgenesis Biotherapeutics: A clinical stage, emerging leader with a pipeline of blockbuster biotherapeutics in ophthalmology

AG-73305 is a first-in-class, bi-specific molecule that simultaneously binds to VEGF and integrins for treating diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD), and other retinal diseases such as retinal vein occlusion (RVO), with US IND filing expected in early 2022.

For additional information and collaboration opportunities with Allgenesis, please send emails to or

About Allgenesis Biotherapeutics Inc.

Allgenesis is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, nAMD, and other retinal diseases such as RVO, AG-86893 for pterygium, and AG-80308 for Dry Eye Disease.

About AG-73305

AG-73305 is a first-in-class molecule specifically designed for the treatment of DME, nAMD, and other retinal diseases such as RVO. AG-73305 is a single fusion protein that simultaneously binds with high potency and specificity to VEGF and integrins, which are known to be involved in retinal diseases. AG-73305 has the potential to treat anti-VEGF responders and non-responders.